Healthcare Giants or Medical Innovators? XLV and PINK Are Built for Different Investors. One fund backs medical breakthroughs and charity, while the other favors industry giants and steady income. Compare their strategies and portfolio makeup.
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors It's another step in Eli Lilly's quest to cement its lead in the chronic weight management market.
Why WeightWatchers (WW) Stock Is Trading Up Today What Happened? Shares of personal wellness company WeightWatchers (
NASDAQ:WW ) jumped 6.3% in the afternoon session after the company announced its Weight Wat...
AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam AbCellera Biologics (
NASDAQ:ABCL ) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said during a company presentation focused on the biotech’s pipeline and lead clinical program.
Booth said
Stock Market Today, June 4: Broadcom Drags on Nasdaq at Midday Broadcom’s weak AI-chip guidance rattled semiconductors and raised questions about tech valuations today, June 4, 2026.
Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies Weight Watchers joins LillyDirect for GLP-1 access as Eli Lilly signs a kidney disease research pact with Ascidian worth up to $1.9 billion.
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare.
3 Reasons Eli Lilly Remains a Buy The shares are up more than 13% this year, and the pharmaceutical company has several other factors that could drive its stock higher.
Avascular Necrosis Market Size, Industry Share By 2035 The most recent research report on the "Avascular Necrosis Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts,
Prediction: Eli Lilly Will Be Worth More Than SpaceX in 2 Years SpaceX looks like a rocket, but don't fly too close to the sun. Here's why Eli Lilly is likely a better stock to own.
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Year, According to Wall Street Wall Street analysts expect market-beating returns from healthcare and communication services stocks over the next year.
Vanguard (VHT) Vs. Simplify (PINK): Which Healthcare ETF Is the Better Buy for Investors? Explore how two healthcare ETFs stack up in cost, yield, and strategy, with one fund emphasizing innovation and charitable impact.
Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.
